Ariana Pelosci | Authors

August 07, 2022

Comparable outcomes seen with sintilimab vs pembrolizumab in patients with treatment-naïve metastatic non–small cell lung cancer.

June 09, 2022

The addition of tucatinib to standard of care maintenance in the first-line setting for patients with HER2-positive metastatic breast cancer will be examined in the ongoing phase 3 HER2CLIMB-05 trial.

June 07, 2022

Treatment with pembrolizumab monotherapy demonstrated the best response in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more, according to a correlative analysis conducted with 3-years of follow-up.

June 06, 2022

Patients with platinum-sensitive ovarian cancer treated with maintenance rucaparib in the ATHENA-MONO trial showed a significant improvement in progression-free survival when compared with placebo in the first-line setting, regardless of HRD status.

June 05, 2022

In elderly frail patients with relapsed/refractory multiple myeloma, treatment with ixazomib plus daratumumab achieved favorable response rates.

May 18, 2022

An individualized starting dose of niraparib, determined by weight and platelet count, continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status,